Does lapatinib have potential in early management of progressive prostate cancer?

A recently published report of a Phase II clinical trial conducted by the Eastern Cooperative Oncology Group (ECOG) suggests that  the tyrosine kinase inhibitor (TKI) lapatinib (Tykerb) may have clinically significant effects in the treatment of men with progressive prostate cancer after first-line therapy. … READ MORE …

Tykerb not effective in treatment of prostate cancer

Like many other drugs before it, lapatinib (Tykerb/GlaxoSmithKline) appears to have very limited clinical activity in prostate cancer according to a recently published report. … READ MORE …